New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
10:03 EDTDUK, GMCR, CVE, FTI, SYMC, VPHM, RPM, RAS, PDH, MLNX, MXIM, CS, CLF, CELG, BSXOn The Fly: Analyst Upgrade Summar
Today's noteworthy upgrades include: Boston Scientific (BSX) upgraded to Outperform from Neutral at Credit Suisse... Celgene (CELG) upgraded to Buy from Neutral at BofA/Merrill... Cliffs Natural (CLF) upgraded to Buy from Hold at Deutsche Bank... Credit Suisse (CS) upgraded to Outperform from Neutral at Exane BNP Paribas... Maxim Integrated (MXIM) upgraded to Outperform from Perform at Oppenheimer... Mellanox (MLNX) upgraded to Buy from Neutral at UBS... PetroLogistics (PDH) upgraded to Buy from Neutral at Citigroup... RAIT Financial (RAS) upgraded to Outperform from Market Perform at FBR Capital... RPM (RPM) upgraded to Perform from Underperform at Oppenheimer... ViroPharma (VPHM) upgraded to Buy from Neutral at BofA/Merrill... Symantec (SYMC) upgraded to Overweight from Equal Weight at Morgan Stanley... FMC Technologies (FTI) upgraded to Overweight from Equal Weight at Morgan Stanley... Cenovus Energy (CVE) upgraded to Overweight from Neutral at JPMorgan... Green Mountain (GMCR) upgraded to Buy from Hold at Argus... Duke Energy (DUK) upgraded to Buy from Neutral at UBS.
News For BSX;CELG;CLF;CS;MXIM;MLNX;PDH;RAS;RPM;VPHM;SYMC;FTI;CVE;GMCR;DUK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 8, 2014
07:59 EDTRPMRPM comments on SPHC plan of reorganization
On September 26, 2014, SPHC filed its plan of reorganization in Delaware Bankruptcy Court. The plan memorializes the settlement in principle reached with representatives of current and future asbestos claimants. As previously reported, a trust will be established to resolve all current and future Bondex asbestos claims, an injunction will be issued by the court that will permanently protect SPHC, RPM International Inc., their affiliates, and other parties from current and future asbestos claims, and SPHC will emerge from bankruptcy and will be reconsolidated with RPM. RPM currently anticipates that the plan's effective date and the reconsolidation of SPHC's financial results will occur in RPM's fiscal 2015 third quarter, but the actual timeline could change based on a variety of factors beyond the control of SPHC and RPM. The impact of the completion of this transaction on RPM's 2015 fiscal year will be dependent on specific timing and related transaction costs. On an annualized basis, SPHC has revenues of approximately $400M. CEO Frank Sullivan said, "We look forward to plan confirmation for SPHC and its emergence from bankruptcy. While the amounts required to fund a 524g trust are substantial from a financial perspective, this transaction will be good for RPM shareholders, both in terms of our ongoing operations and as a process which will bring finality to the Bondex asbestos liability."
07:57 EDTRPMRPM sees FY16 EPS $2.70-$2.90, consensus $2.74
Subscribe for More Information
07:42 EDTMLNXMellanox initiated with a Buy at Ladenburg
Target $51.
07:34 EDTRPMRPM backs FY15 EPS $2.38-$2.42, consensus $2.42
Backs FY14 consolidated sales up 6%-8%, consensus $4.65B; Backs FY15 industrial sales up 6%-8%; Backs FY15 consumer sales up 5%-7%.
07:33 EDTRPMRPM expects FY15 quarterly results to follow different pattern from FY14
Subscribe for More Information
07:31 EDTRPMRPM reports Q1 EPS 73c, consensus 79c
Reports Q1 revenue $1.20B, consensus $1.23B
07:27 EDTSYMCSymantec volatility flat, in advanced talks to split company in two, report
Subscribe for More Information
07:24 EDTBSXFDA Circulatory Systems Devices Panel to hold a meeting
The Committee discusses, makes recommendations and votes on information related to the Pre-Market Approval Application regarding Boston Scientific’s WATCHMAN Left Atrial Appendage (LAA) Closure Technology in a meeting being held in Gaithersburg, Maryland on October 8 at 8 am. Webcast Link
07:13 EDTCSBank dealers agree to revised derivatives rules, FT reports
Subscribe for More Information
07:11 EDTCELGEuropean Academy of Dermatology and Venereology to hold a conference
23rd EADV Congress is being held in Amsterdam, The Netherlands on October 8-12.
06:01 EDTCLFCliffs Natural implied volatility of 99 at upper end of index mean range
Subscribe for More Information
05:46 EDTSYMCSymantec in advanced talks to split company in two, Bloomberg reports
Subscribe for More Information
October 7, 2014
15:16 EDTCLFCliffs Natural volatility increases as shares trend lower
Cliffs Natural October weekly call option implied volatility is at 115, October is at 89, November is at 88, December is at 89, January is at 79; compared to its 26-week average of 48 according to Track Data, suggesting larger price movement.
15:16 EDTRPMNotable companies reporting before tomorrow's open
Subscribe for More Information
12:09 EDTGMCROn The Fly: Midday Wrap
Subscribe for More Information
11:03 EDTDUKDuke Energy Renewable Services signs five-year service agreements
Subscribe for More Information
10:02 EDTGMCROn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:31 EDTCELGCelgene to present long-term efficacy and safety data on oral Otezla
Celgene International Sŕrl, a wholly-owned subsidiary of Celgene Corporation, announced that the latest research findings on OTEZLA, the company’s oral, selective inhibitor of phosphodiesterase 4, in plaque psoriasis and psoriatic arthritis will be presented at the 23rd European Academy of Dermatology and Venereology Congress in Amsterdam, October 8 – 12. In total, 11 abstracts will be presented at the meeting. OTEZLA data to be presented include long-term results from Celgene’s pivotal trial, ESTEEM 2 and pooled analyses of safety and tolerability results from the ESTEEM 1 and 2 studies in patients with moderate to severe plaque psoriasis. Additional analyses will evaluate the effect of OTEZLA on pruritus, difficult-to-treat areas such as nail and scalp, and palmoplantar psoriasis, work productivity and improvements in health-related quality of life. An analysis of long-term results from the PALACE clinical trial program evaluating OTEZLA in patients with active psoriatic arthritis will also be presented at the meeting. The analysis assesses the effect of OTEZLA treatment through 52 weeks on the signs and symptoms of psoriatic arthritis, including enthesitis and dactylitis in patients with pre-existing enthesitis or dactylitis.
07:24 EDTCELGAlliance for Regenerative Medicine
Subscribe for More Information
05:25 EDTGMCRKeurig Green Mountain initiated with a Buy at Goldman
Goldman Sachs started shares of Keurig Green Mountain with a Buy rating saying the company is entering a period of accelerating sales and earnings growth. The firm expects growth to be driven by Keurig's Hot system and incremental contribution from the Cold platform. It set a $166 price target for shares.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use